Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 220.46% | -64.65% | -41.69% | -36.62% | -38.32% |
| Total Depreciation and Amortization | -11.35% | 1.73% | 16.50% | 20.68% | 18.96% |
| Total Amortization of Deferred Charges | -53.85% | -53.85% | -53.85% | -53.85% | -7.14% |
| Total Other Non-Cash Items | 35.70% | 39.05% | 35.63% | 20.79% | 6.21% |
| Change in Net Operating Assets | 214.88% | 96.08% | 38.48% | -71.71% | -174.05% |
| Cash from Operations | 264.64% | -36.49% | -35.77% | -44.55% | -137.16% |
| Capital Expenditure | 13.41% | -1.99% | -17.10% | -51.00% | -12.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.99% | 156.53% | 103.90% | 165.15% | 114.54% |
| Cash from Investing | -83.59% | 130.70% | 99.44% | 157.37% | 105.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.58% | 3.81% | -47.04% | -50.86% | -28.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28.58% | 3.81% | -47.04% | -50.86% | -28.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,223.90% | 49.25% | -117.83% | 147.48% | -136.20% |